{
    "root": "3953e8ee-89f6-4455-9551-e6bddf5bf6be",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Fenofibrate",
    "value": "20250509",
    "ingredients": [
        {
            "name": "FENOFIBRATE",
            "code": "U202363UOS",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5001"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17992"
        },
        {
            "name": "SOYBEAN LECITHIN",
            "code": "1DI56QDM62",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_61995"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_189560"
        }
    ],
    "indications": {
        "text": "fenofibrate tablets peroxisome proliferator receptor alpha ( ppar\u03b1 ) activator indicated adjunct diet : \u2022 reduce elevated ldl-c , total-c , tg apo b , increase hdl-c adult patients primary hypercholesterolemia mixed dyslipidemia ( 1.1 ) . \u2022 treatment adult patients severe hypertriglyceridemia ( 1.2 ) . important limitations : fenofibrate shown reduce coronary heart disease morbidity mortality patients type 2 diabetes mellitus ( 5.1 ) .",
        "doid_entities": [
            {
                "text": "dyslipidemia (DOID:3146)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3146"
            },
            {
                "text": "coronary heart disease (DOID:3393)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3393"
            },
            {
                "text": "heart disease (DOID:114)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_114"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "type 2 diabetes mellitus (DOID:9352)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9352"
            },
            {
                "text": "diabetes (DOID:9351)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9351"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 primary hypercholesterolemia mixed dyslipidemia : initial dose 145 mg daily ( 2.2 ) . \u2022 severe hypertriglyceridemia : initial dose 48 145 mg daily . maximum dose 145 mg ( 2.3 ) . \u2022 renally impaired patients : initial dose 48 mg daily ( 2.4 ) . \u2022 geriatric patients : select dose basis renal function ( 2.5 ) \u2022 maybe taken without regard meals ( 2.1 ) .",
        "doid_entities": [
            {
                "text": "dyslipidemia (DOID:3146)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3146"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "fenofibrate tablets , usp available ; 145 mg tablets white off-white , oval , biconvex film coated tablets , debossed ' j ' one side '136 ' side , available : bottles 30 tablets ndc 68788-8106-3bottles 60 tablets ndc 68788-8106-6 bottles 90 tablets ndc 68788-8106-9bottles 100 tablets ndc 68788-8106-1storage store 20o 25oc ( 68o 77o f ) [ usp controlled room temperature ] . keep reach children . protect moisture .",
    "adverseReactions": "fenofibrate tablets contraindicated : \u2022 patients severe renal impairment , including receiving dialysis [ pharmacology ( 12.3 ) ] . \u2022 patients active liver disease , including primary biliary cirrhosis unexplained persistent liver function abnormalities [ ( 5.3 ) ] . \u2022 patients preexisting gallbladder disease [ ( 5.5 ) ] . \u2022 nursing mothers [ ( 8.3 ) ] . \u2022 patients known hypersensitivity fenofibrate fenofibric acid [ ( 5.9 ) ] .",
    "indications_original": "Fenofibrate tablets are peroxisome proliferator receptor alpha (PPAR\u03b1) activator indicated as an adjunct to diet: \u2022 To reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.1 ). \u2022 For treatment of adult patients with severe hypertriglyceridemia ( 1.2 ). Important Limitations of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus ( 5.1 ).",
    "contraindications_original": "\u2022 Primary hypercholesterolemia or mixed dyslipidemia: Initial dose of 145 mg once daily ( 2.2 ). \u2022 Severe hypertriglyceridemia: Initial dose of 48 to 145 mg once daily. Maximum dose is 145 mg ( 2.3 ). \u2022 Renally impaired patients: Initial dose of 48 mg once daily ( 2.4 ). \u2022 Geriatric patients: Select the dose on the basis of renal function ( 2.5 ) \u2022 Maybe taken without regard to meals ( 2.1 ).",
    "warningsAndPrecautions_original": "Fenofibrate tablets, USP are available in;145 mg tablets are white to off-white, oval, biconvex film coated tablets, debossed with 'J' on one side and '136' on other side, available in:Bottles of 30 Tablets\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 68788-8106-3Bottles of 60 Tablets\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 68788-8106-6\n                  Bottles of 90 Tablets\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 68788-8106-9Bottles of 100 Tablets\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0NDC 68788-8106-1Storage Store at 20o to 25oC (68o to 77o F) [See USP Controlled Room Temperature]. Keep out of reach of children. Protect from moisture.",
    "adverseReactions_original": "Fenofibrate tablets are contraindicated in: \n                     \u2022 patients with severe renal impairment, including those receiving dialysis [see Clinical Pharmacology (12.3)].\u00a0 \n                     \u2022 patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities [see Warnings and Precautions (5.3)].\n                     \n                     \u2022 patients with preexisting gallbladder disease [see Warnings and Precautions (5.5)]. \n                     \n                     \u2022 nursing mothers [see Use in Specific Populations (8.3)].\n                     \n                     \u2022 patients with known hypersensitivity to fenofibrate or fenofibric acid [see Warnings and Precautions(5.9)].",
    "drug": [
        {
            "name": "Fenofibrate",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5001"
        }
    ]
}